Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02402920 · ClinicalTrials.gov registry record · Phase 1

Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer

A Phase 1 study of Neuroendocrine Neoplasm and Extensive Stage Small Cell Lung Carcinoma, sponsored by M.D. Anderson Cancer Center.

Completed
Registry status
Phase 1
Development phase
83
Enrollment target
1
Study location

NCT02402920 is a Phase 1 study of Neuroendocrine Neoplasm and Extensive Stage Small Cell Lung Carcinoma that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 83 participants, below the 118-participant average among 6 other Neuroendocrine Neoplasm trials with a reported enrollment target (30% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02402920, a Phase 1 study of Neuroendocrine Neoplasm and Extensive Stage Small Cell Lung Carcinoma, has completed, sponsored by M.D. Anderson Cancer Center.

COMPLETED
Registry status
Phase 1
Development phase
83 participants
Enrollment target
1
Study location

Study Summary

This phase I trial studies the side effects and best dose of pembrolizumab when given together with chemoradiotherapy or radiation therapy in treating patients with small cell lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays to kill cancer cells and shrink tumors. Giving chemotherapy with radiation therapy may kill more cancer cells. Giving pembrolizumab with chemoradiotherapy or radiation therapy may be a better treatment for small cell lung cancer.

Conditions Studied

Neuroendocrine Neoplasm Extensive Stage Small Cell Lung Carcinoma Limited Stage Small Cell Lung Carcinoma

Interventions

  • BIOLOGICAL Pembrolizumab
  • DRUG Carboplatin
  • DRUG Cisplatin
  • OTHER Laboratory Biomarker Analysis
  • DRUG Etoposide

Study Locations (1)

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 83 participants
Start Date 2015-07-22
Est. Completion 2026-02-09
Phase Phase 1

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02402920

The ClinicalTrials.gov registry entry for NCT02402920 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 118-participant average among 6 other Neuroendocrine Neoplasm trials with a reported enrollment target (30% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Neuroendocrine Neoplasm appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.

NCT02402920 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT02402920 about?

NCT02402920 is a clinical study titled "Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer". This phase I trial studies the side effects and best dose of pembrolizumab when given together with chemoradiotherapy or radiation therapy in treating patients with small cell lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the c...

What is the current status of trial NCT02402920?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 83 participants. The study started on 2015-07-22. Estimated completion is 2026-02-09.

What conditions does trial NCT02402920 study?

This clinical trial studies the following conditions: Neuroendocrine Neoplasm, Extensive Stage Small Cell Lung Carcinoma, Limited Stage Small Cell Lung Carcinoma.

What interventions are being tested in trial NCT02402920?

The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Carboplatin (DRUG), Cisplatin (DRUG), Laboratory Biomarker Analysis (OTHER), Etoposide (DRUG).

Who is sponsoring clinical trial NCT02402920?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02402920 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Neuroendocrine Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Neuroendocrine Neoplasm

All registered trials for this condition

Extensive Stage Small Cell Lung Carcinoma

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.